🇺🇸 FDA
Pipeline program

Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

Debio 0123-SCLC-104

Phase 1 other active

Quick answer

Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy. for Small cell lung cancer is a Phase 1 program (other) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharm Research Associates (UK) Limited
Indication
Small cell lung cancer
Phase
Phase 1
Modality
other
Status
active

Clinical trials